Do You Need Menopause Hormone Therapy?

What Menopause Hormone Therapy Actually Is

Menopause hormone therapy is a category of treatments that replaces estrogen, often combined with a progestogen, to compensate for the sharp decline in ovarian hormone production at menopause. The primary goal is symptom relief, though bone protection and, in certain populations, cardiovascular benefit are also documented. The Menopause Society 2023 position statement states that "hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause."

Types of MHT Formulations

Several distinct formulations exist, and the choice between them affects both efficacy and risk:

• Systemic estrogen-only therapy (ET): prescribed to women who have had a hysterectomy; comes as oral tablets, transdermal patches, gels, or sprays.
• Combined estrogen-progestogen therapy (EPT): used in women with an intact uterus to prevent endometrial hyperplasia; the progestogen component is delivered orally, transdermally, or as a levonorgestrel-releasing intrauterine device.
• Low-dose vaginal estrogen: creams, rings, or tablets applied locally for genitourinary syndrome; systemic absorption is minimal at approved doses.
• Bioidentical hormones: 17-beta estradiol and micronized progesterone (Prometrium) are FDA-approved bioidentical options; compounded preparations lack standardized dosing data.

The Timing Hypothesis

The "timing hypothesis" or "window of opportunity" concept holds that MHT started close to menopause onset carries a more favorable cardiovascular profile than therapy started a decade or more later. The Kronos Early Estrogen Prevention Study (KEEPS, NCT00154180) enrolled 727 recently menopausal women aged 42-58 and found that oral conjugated equine estrogen and transdermal estradiol did not accelerate subclinical atherosclerosis progression compared with placebo over 4 years. Starting MHT well after menopause, when atherosclerotic plaques are already established, may not carry the same safety profile.

Who Is Most Likely to Benefit From MHT

The decision to use MHT is not uniform. Several clinical profiles consistently show clear benefit-to-risk ratios that favor treatment.

Women With Moderate-to-Severe Vasomotor Symptoms

Vasomotor symptoms, hot flashes and night sweats, affect roughly 75-80% of women during the menopausal transition. A 2015 JAMA Internal Medicine analysis tracking 255 women over 14 years found that median duration of frequent vasomotor symptoms was 7.4 years, with symptoms persisting over 11 years in women who first experienced them in perimenopause. For women whose quality of life, sleep, and work performance are significantly disrupted, MHT provides the most consistent and substantial relief available.

Randomized controlled data remain clear on efficacy. A Cochrane review of 24 trials found that compared with placebo, estrogen-based MHT reduced hot flash frequency by approximately 75% and severity scores by 87%.

Women With Genitourinary Syndrome of Menopause

Genitourinary syndrome of menopause (GSM) encompasses vaginal dryness, dyspareunia, urinary urgency, and recurrent urinary tract infections. Unlike vasomotor symptoms, GSM does not resolve spontaneously and tends to worsen over time without treatment. Low-dose local vaginal estrogen is the first-line pharmacologic option. ACOG Practice Bulletin 141 supports its use and notes that systemic estrogen absorption from vaginal preparations at standard doses is below the threshold likely to cause endometrial stimulation in most women.

Women With Premature Ovarian Insufficiency

Women diagnosed with premature ovarian insufficiency (POI), spontaneous menopause before age 40, face decades of estrogen deficiency that significantly raises their risks for osteoporosis, cardiovascular disease, and cognitive decline. The European Society of Human Reproduction and Embryology guideline (ESHRE 2016) recommends MHT or combined oral contraceptives until at least the average age of natural menopause (approximately 51 years) to mitigate these risks. In this population, MHT is not considered optional management. It is considered health-protective.

Understanding the Risks: What the Evidence Actually Shows

The Women's Health Initiative (WHI) trial published in 2002 triggered widespread discontinuation of MHT based on reported increases in breast cancer and cardiovascular events. Subsequent re-analyses have substantially changed the clinical picture.

Breast Cancer Risk in Context

The absolute breast cancer risk increase in the WHI combined EPT arm was small. The trial (Rossouw et al., JAMA 2002) reported an excess of approximately 8 cases per 10,000 women per year of combined use compared with placebo. That figure translates to fewer than 1 additional case per 1,000 women annually. The estrogen-only arm (women post-hysterectomy) showed no statistically significant increase in breast cancer risk over 7.1 years of follow-up, and a 2020 follow-up analysis in JAMA showed that women who used estrogen-only therapy had a lower breast cancer mortality than placebo recipients (hazard ratio 0.60, 95% CI 0.43-0.83).

Breast cancer risk is higher with combined EPT than with ET alone, and risk appears to increase with duration of use. Using micronized progesterone (as opposed to synthetic progestins) may carry a lower breast cancer risk, though head-to-head randomized trial data are limited. The E3N cohort study (N=80,377 French women) found that combined estrogen plus micronized progesterone was not associated with a statistically significant increase in breast cancer risk, while synthetic progestins were.

Cardiovascular Risk: Age and Timing Matter Enormously

The cardiovascular story from WHI was heavily confounded by the average participant age of 63, meaning most women were enrolled well past the timing window. A re-analysis by Manson et al. In JAMA 2017 stratified WHI outcomes by age at enrollment and found that women aged 50-59 who used combined EPT had a non-significant trend toward lower all-cause mortality compared with placebo (hazard ratio 0.87, 95% CI 0.69-1.10). Coronary heart disease risk was not significantly elevated in this younger age group.

Transdermal estradiol appears to carry a lower venous thromboembolism (VTE) risk than oral estrogens. A BMJ case-control study (N=approximately 1 million women) found that oral estrogens doubled VTE risk relative to non-use, while transdermal preparations did not significantly increase VTE risk. For women at elevated baseline VTE risk, transdermal delivery is the preferred route.

Stroke Risk

Oral estrogens are associated with a modest increase in ischemic stroke risk, particularly at higher doses. Transdermal estradiol at standard doses does not appear to carry the same elevation. The ESTHER study found that oral but not transdermal estrogen use was associated with increased stroke risk (OR 1.89, 95% CI 1.24-2.88 for oral; OR 0.95, 95% CI 0.52-1.72 for transdermal).

Who Should Not Use Systemic MHT

Absolute contraindications to systemic MHT exist and should prompt consideration of non-hormonal alternatives:

• Active or recent estrogen-receptor-positive breast cancer
• Undiagnosed abnormal vaginal bleeding
• Active or prior venous thromboembolism not managed on anticoagulation
• Active or recent arterial thromboembolic disease (stroke, MI)
• Known or suspected pregnancy
• Active liver disease with impaired hepatic function

Women with a personal history of endometrial cancer, migraines with aura, or controlled cardiovascular disease are not automatically excluded, but require individualized risk assessment and should discuss options with a specialist.

Non-Hormonal Options for Women Who Cannot or Choose Not to Use MHT

Several FDA-approved and evidence-supported non-hormonal options exist for women with vasomotor symptoms who have contraindications to or personal preferences against MHT.

FDA-Approved Non-Hormonal Medications

Fezolinetant (Veozah): The FDA approved fezolinetant in May 2023 (FDA approval) as the first neurokinin B receptor antagonist for moderate-to-severe vasomotor symptoms. In the SKYLIGHT 1 and SKYLIGHT 2 trials, fezolinetant 45 mg daily reduced hot flash frequency by approximately 60-65% from baseline at week 12 versus roughly 45% for placebo. It carries no estrogen-related risks, making it a genuine alternative for women with hormone-sensitive cancers.

Paroxetine mesylate (Brisdelle): The only SSRI with an FDA-approved indication for vasomotor symptoms. At 7.5 mg daily (below antidepressant doses), it reduces hot flash frequency by about 33-67% in trials. Women taking tamoxifen should avoid paroxetine due to CYP2D6 inhibition that reduces tamoxifen efficacy.

Off-Label but Evidence-Supported Options

• Venlafaxine 37.5-75 mg daily: A 2006 Mayo Clinic trial found venlafaxine reduced hot flash scores by 58% versus 27% placebo at 12 weeks.
• Gabapentin 300 mg three times daily: Modestly effective, particularly for nighttime hot flashes; sedation limits daytime use for many patients.
• Oxybutynin: Some RCT data support off-label use for vasomotor symptoms at 2.5-5 mg daily, though anticholinergic side effects require monitoring.

How to Decide: A Practical Clinical Framework

The decision about MHT cannot be reduced to a simple checklist. It requires weighing symptom severity, personal health history, risk tolerance, and patient preference.

Step 1. Quantify Symptom Burden

Tools like the Menopause Rating Scale (MRS) and the Greene Climacteric Scale provide validated numeric scores to document symptom severity at baseline. Women scoring in the moderate-to-severe range on vasomotor or genitourinary subscales have the strongest indication for active pharmacologic treatment.

Step 2. Assess Baseline Risk Profile

Before initiating MHT, clinicians should evaluate:

• Personal and family history of breast cancer, thromboembolic events, and cardiovascular disease
• DEXA scan results if osteoporosis risk is elevated
• Blood pressure (hypertension increases VTE and stroke risk with oral estrogens)
• Presence of an intact uterus (determines whether a progestogen is required)

Step 3. Choose Route and Regimen Based on Individual Risk

A 2022 NICE guideline update (NG23) recommends transdermal estradiol over oral preparations where VTE risk is a concern, and micronized progesterone (Prometrium 200 mg for 12 days per cycle or 100 mg daily continuously) over synthetic progestins where breast cancer risk is a concern. These are not interchangeable as a class. Route, molecule, and dose each carry distinct risk profiles.

Step 4. Establish a Review Schedule

No fixed endpoint exists for MHT duration. The Menopause Society (2023 position statement) states that "the duration of MHT use should be individualized based on the woman's symptom burden, quality of life, and personal risk profile, reassessed at least annually." Annual review should include blood pressure, any new symptoms, and discussion of whether benefits continue to outweigh risks for that individual.

What the Guidelines Say in 2024 and 2025

The Menopause Society Position

The Menopause Society (formerly NAMS) 2023 position statement (full text via PubMed) is the most current North American clinical reference on this topic. It concludes that "for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture." The statement explicitly rejects a blanket restriction on MHT duration for otherwise healthy women.

ACOG Guidance

ACOG Practice Bulletin 141 (updated position) affirms MHT as appropriate for women with moderate-to-severe menopausal symptoms and supports individualized decision-making rather than age-based cutoffs. ACOG also endorses low-dose vaginal estrogen for GSM without mandatory progestogen opposition in women with an intact uterus, given the minimal systemic absorption at approved doses.

USPSTF Stance

The USPSTF issued a 2017 recommendation (Grade D) against using combined EPT or estrogen-only therapy for the primary prevention of chronic conditions such as cardiovascular disease or dementia in postmenopausal women. This Grade D applies to disease prevention in asymptomatic women, not to symptom treatment. Clinicians and patients often confuse these two distinct indications.

Special Populations

Women After Surgically Induced Menopause

Bilateral oophorectomy before natural menopause creates an abrupt, complete loss of estrogen, often producing more severe symptoms than natural menopause. A Mayo Clinic cohort study found that women who underwent bilateral oophorectomy before age 45 and did not use estrogen therapy had significantly higher all-cause mortality, cardiovascular disease, and cognitive impairment compared with ovary-intact controls. For these women, MHT is particularly strongly supported until at least the average natural menopause age.

Women With Osteoporosis or High Fracture Risk

Estrogen therapy reduces osteoclast activity and maintains bone mineral density. The WHI bone sub-study showed that combined EPT reduced hip fracture incidence by 34% (HR 0.66, 95% CI 0.45-0.98) compared with placebo. For women whose fracture risk justifies MHT, therapy serves a dual purpose. Bisphosphonates or denosumab may be added or substituted if MHT is discontinued.

Women Over 60 or More Than 10 Years Past Menopause

Starting MHT de novo more than 10 years after menopause onset carries a less favorable benefit-risk profile, particularly for cardiovascular outcomes. This group is not automatically excluded from MHT, but initiation requires more detailed cardiovascular risk assessment, typically using a validated tool such as the Framingham Risk Score or ACC/AHA Pooled Cohort Equations, and a frank discussion of current evidence limitations.